-
公开(公告)号：EP3281607B1
公开(公告)日：2019-03-06
申请号：EP17185795.6
申请日：2013-06-18
申请人： LifeCell Corporation
-
公开(公告)号：EP2863840B1
公开(公告)日：2017-08-16
申请号：EP13735107.8
申请日：2013-06-18
申请人： Lifecell Corporation
发明人： ANSORGE, Heather , LAPITAN, Lawrence , HAYZLETT, Mark , KABARIA, Nimesh , HULL, Raymond , SUN, Wenquan , TAENZER, Michael , AMATO, Matthew , ROOCK, Timothy , LEE, Dennis
CPC分类号： A61F2/12 , A61B90/02 , A61F2/0059 , A61F2210/0076 , A61F2220/0016 , A61F2220/0025 , A61F2220/0033 , A61F2220/005 , A61F2220/0075 , A61F2220/0091 , A61F2230/0004 , A61F2230/0045 , A61F2230/0086 , A61F2230/0089 , A61F2230/0093 , A61F2250/0003 , A61F2250/0024 , A61F2250/0031 , A61F2250/0051 , A61F2250/0071
摘要： Improved prostheses comprising a tissue expander and a graft material are disclosed herein. Also disclosed are methods of making prostheses and methods of treatment using the prostheses.
摘要翻译： 1。一种假体，其包括组织扩张器和一个或多个移植材料样本，其中所述组织扩张器以允许组织扩张器和所述一个或多个移植材料样本被植入的方式附接到所述一个或多个移植材料样本 在患者中作为单一假体; 并且其中组织扩张器以允许组织扩张器和移植材料在植入后的一段时间之后分离的方式附接到移植材料的一个或多个样本，以允许从植入部位移除组织扩张器，同时离开 所述植入物部位内的移植物材料，所述假体包括组织扩张器，所述组织扩张器在表面上具有模制的凹槽，槽，通道或其他浅腔空间，并且其中所述移植物材料位于所述凹槽，狭槽，通道或其他浅腔室空间内 将移植材料固定到组织扩张器。
-
公开(公告)号：EP4438069A2
公开(公告)日：2024-10-02
申请号：EP24181813.7
申请日：2014-09-05
申请人： LifeCell Corporation
发明人： CHEN, Yi , KABARIA, Nimesh , WANG, Kai-Roy , XU, Hui , LEAMY, Patrick , WAN, Hua , SUN, Wenquan , HUANG, Li Ting
IPC分类号： A61L27/36
CPC分类号： A61L27/3633 , A61L27/3687 , A61L27/3695
摘要： Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure.
-
公开(公告)号：EP3501558A1
公开(公告)日：2019-06-26
申请号：EP18210458.8
申请日：2012-12-18
申请人： LifeCell Corporation
发明人： HAYZLETT, Mark , MUNOZ, Ivis , KABARIA, Nimesh , CZECUGA, Joshua
IPC分类号： A61L27/36
摘要： The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection.
-
公开(公告)号：EP3030272A1
公开(公告)日：2016-06-15
申请号：EP14776766.9
申请日：2014-09-05
申请人： Lifecell Corporation
发明人： CHEN, Yi , KABARIA, Nimesh , WANG, Kai-Roy , XU, Hui , LEAMY, Patrick , WAN, Hua , SUN, Wenquan , HUANG, Li Ting
IPC分类号： A61L27/36
CPC分类号： A61L27/3687 , A61L27/3633 , A61L27/3695
摘要： Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen- containing tissue matrix to reduce a human immune response to the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure.
-
-
公开(公告)号：EP3030272B1
公开(公告)日：2019-05-29
申请号：EP14776766.9
申请日：2014-09-05
申请人： LifeCell Corporation
发明人： CHEN, Yi , KABARIA, Nimesh , WANG, Kai-Roy , XU, Hui , LEAMY, Patrick , WAN, Hua , SUN, Wenquan , HUANG, Li Ting
IPC分类号： A61L27/36
-
公开(公告)号：EP3281607A1
公开(公告)日：2018-02-14
申请号：EP17185795.6
申请日：2013-06-18
申请人： LIFECELL CORPORATION
发明人： ANSORGE, Heather , LAPITAN, Lawrence , HAYZLETT, Mark , KABARIA, Nimesh , HULL, Raymond , SUN, Wenquan , TAENZER, Michael , AMATO, Matthew , ROOCK, Timothy , LEE, Dennis
CPC分类号： A61F2/12 , A61B90/02 , A61F2/0059 , A61F2210/0076 , A61F2220/0016 , A61F2220/0025 , A61F2220/0033 , A61F2220/005 , A61F2220/0075 , A61F2220/0091 , A61F2230/0004 , A61F2230/0045 , A61F2230/0086 , A61F2230/0089 , A61F2230/0093 , A61F2250/0003 , A61F2250/0024 , A61F2250/0031 , A61F2250/0051 , A61F2250/0071
摘要： Improved prostheses comprising a tissue expander and a graft material are disclosed herein. Also disclosed are methods of making prostheses and methods of treatment using the prostheses.
摘要翻译： 本文公开了包括组织扩张器和移植物材料的改进的假体。 还公开了使用假体制造假体和治疗方法的方法。
-
公开(公告)号：EP2793965A1
公开(公告)日：2014-10-29
申请号：EP12809973.6
申请日：2012-12-18
申请人： Lifecell Corporation
发明人： HAYZLETT, Mark , MUNOZ, Ivis , KABARIA, Nimesh , CZECZUGA, Joshua
IPC分类号： A61L27/36
CPC分类号： A61F2/02 , A61L27/3604 , A61L27/3608 , A61L27/3612 , A61L27/362 , A61L27/3625 , A61L27/3683 , A61L27/3691 , A61L2400/06 , A61L2430/34 , A61L2430/40
摘要： The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection. The disclosure also includes methods of treating tissue using the tissue fillers. The tissue particles can each be formed of tissue fragments having certain sizes.
摘要翻译： 本公开提供组织填充剂。 组织填充剂可以包括由无细胞组织基质片段形成的多个组织颗粒。 组织填充物可用于填充组织部位，例如组织切除后形成的空隙。
-
公开(公告)号：EP4052735A1
公开(公告)日：2022-09-07
申请号：EP22169285.8
申请日：2014-09-05
申请人： LifeCell Corporation
发明人： CHEN, Yi , KABARIA, Nimesh , WANG, Kai-Roy , XU, Hui , LEAMY, Patrick , WAN, Hua , SUN, Wenquan , HUANG, Li Ting
IPC分类号： A61L27/36
摘要： Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.01 秒)
